

Siv Jonsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1552156/publications.pdf>

Version: 2024-02-01

39
papers

1,137
citations

471061

17
h-index

395343

33
g-index

39
all docs

39
docs citations

39
times ranked

1819
citing authors

#	ARTICLE	IF	CITATIONS
1	Population pharmacokinetics of cefotaxime in intensive care patients. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 251-258.	0.8	5
2	Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. <i>Clinical Cancer Research</i> , 2022, 28, 1363-1371.	3.2	2
3	Population pharmacokinetic analysis of etrolizumab in patients with moderately to severely active ulcerative colitis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 1244-1255.	1.3	5
4	Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety. <i>Pharmaceutical Research</i> , 2021, 38, 593-605.	1.7	4
5	Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item score models. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 309-317.	1.3	7
6	Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients. <i>Haematologica</i> , 2020, 105, 1443-1453.	1.7	18
7	Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 894-903.	1.3	9
8	Model-based evaluation of low-dose factor VIII prophylaxis in haemophilia A. <i>Haemophilia</i> , 2019, 25, 408-415.	1.0	10
9	Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1326-1336.	1.1	45
10	Pharmacometric Analysis of the Relationship Between Absolute Lymphocyte Count and Expanded Disability Status Scale and Relapse Rate, Efficacy End Points, in Multiple Sclerosis Trials. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1284-1294.	1.0	9
11	A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 733-746.	1.6	13
12	Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 977-988.	2.3	20
13	Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 341-358.	2.3	240
14	Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 724-732.	1.9	33
15	Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep Vein Thrombosis or Pulmonary Embolism. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 222-232.	1.3	10
16	Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 459-467.	0.8	21
17	A diagnostic tool for population models using non-compartmental analysis: The ncappc package for R. <i>Computer Methods and Programs in Biomedicine</i> , 2016, 127, 83-93.	2.6	42
18	Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1079-1090.	1.6	27

#	ARTICLE	IF	CITATIONS
19	Population pharmacokinetics of edoxaban in patients with symptomatic deepâ€vein thrombosis and/or pulmonary embolismâ€”the Hokusaiâ€VTE phase 3 study. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1374-1387.	1.1	18
20	Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1268-1279.	1.0	38
21	A Time-to-Event Model for Acute Rejections in Paediatric Renal Transplant Recipients Treated with Cyclosporin A. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, n/a-n/a.	1.1	14
22	Role of Modelling and Simulation. <i>Clinical Pharmacokinetics</i> , 2012, 51, 69-76.	1.6	14
23	Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers. <i>NeuroImage</i> , 2012, 61, 849-856.	2.1	27
24	Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4230-4237.	1.4	46
25	Contribution of Modeling and Simulation Studies in the Regulatory Review: A European Regulatory Perspective. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2011, , 15-36.	0.2	5
26	Longâ€Term Changes in Cyclosporine Pharmacokinetics After Renal Transplantation in Children: Evidence for Saturable Presystemic Metabolism and Effect of <i>NR1H2</i> Polymorphism. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 581-597.	1.0	25
27	Pharmacokinetics and dose requirements of factor VIII over the age range 3â€74Âyears. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 989-998.	0.8	142
28	Estimation of Cefuroxime Dosage Using Pharmacodynamic Targets, MIC Distributions, and Minimization of a Risk Function. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 1270-1281.	1.0	11
29	Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 77-90.	0.7	71
30	Developmental pharmacokinetics of ciclosporin â€” a population pharmacokinetic study in paediatric renal transplant candidates. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 772-784.	1.1	54
31	Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 25, 123-132.	1.9	15
32	Population Pharmacokinetic Modelling and Estimation of Dosing Strategy for NXY-059, a Nitrone Being Developed for Stroke. <i>Clinical Pharmacokinetics</i> , 2005, 44, 863-878.	1.6	15
33	The back-step methodâ€”Method for obtaining unbiased population parameter estimates for ordered categorical data. <i>AAPS Journal</i> , 2004, 6, 13-22.	2.2	4
34	Estimating Bias in Population Parameters for Some Models for Repeated Measures Ordinal Data Using NONMEM and NLMIXED. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2004, 31, 299-320.	0.8	17
35	A rational approach for selection of optimal covariate-based dosing strategies*1. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 7-19.	2.3	15
36	Lactational Exposure and Neonatal Kinetics of Methylmercury and Inorganic Mercury in Mice. <i>Toxicology and Applied Pharmacology</i> , 1999, 154, 160-169.	1.3	25

#	ARTICLE	IF	CITATIONS
37	Kinetics of Methylmercury and Inorganic Mercury in Lactating and Nonlactating Mice. Toxicology and Applied Pharmacology, 1998, 151, 319-329.	1.3	35
38	Toxicokinetics of Lead in Lactating and Nonlactating Mice. Toxicology and Applied Pharmacology, 1996, 136, 342-347.	1.3	21
39	Kinetic Observations in Neonatal Mice Exposed to Lead via Milk. Toxicology and Applied Pharmacology, 1996, 140, 13-18.	1.3	5